We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Benefit of Adding Fish Oil to the Nutrition of Critically Ill Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00142220
First Posted: September 2, 2005
Last Update Posted: September 11, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Fresenius AG
Information provided by:
University Medicine Greifswald
  Purpose
We study whether an increased proportion of omega-3-fatty acids (contained in fish oil) in the nutrition of critically ill patients reduces systemic inflammation.

Condition Intervention Phase
Sepsis Syndrome Drug: Defined percentage of omega-3-fatty acids Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Comparison Between Two Different Proportions of Omega-3- and Omega-6-Fatty Acids in the Parenteral Nutrition of Critically Ill Patients

Resource links provided by NLM:


Further study details as provided by University Medicine Greifswald:

Primary Outcome Measures:
  • level of IL-6 in serum
  • HLA-expression on monocytes

Secondary Outcome Measures:
  • number of nosocomial infections
  • days on mechanical ventilation
  • duration of ICU stay
  • mortality
  • SOFA score

Estimated Enrollment: 160
Study Start Date: January 2004
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • indication for parenteral nutrition

Exclusion Criteria:

  • hypertriglyceridemia
  • coagulation disorder
  • decompensated liver cirrhosis or acute liver failure
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00142220


Locations
Germany
Internistische ITS
Greifswald, Germany, 17475
Sponsors and Collaborators
University Medicine Greifswald
Fresenius AG
Investigators
Principal Investigator: Sigrun Friesecke, Dr. University Medicine Greifswald
  More Information

ClinicalTrials.gov Identifier: NCT00142220     History of Changes
Other Study ID Numbers: OMEGAVEN
First Submitted: August 31, 2005
First Posted: September 2, 2005
Last Update Posted: September 11, 2006
Last Verified: September 2006

Additional relevant MeSH terms:
Critical Illness
Systemic Inflammatory Response Syndrome
Toxemia
Sepsis
Disease Attributes
Pathologic Processes
Inflammation
Shock
Infection